 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > OXIS International, Inc.
 |
OXIS International, Inc. |
 |
 |
 |
PROFILE |
 |
Don't stress out -- call OXIS International. The company specializes in diagnosing, treating, and preventing oxidative stress-related diseases. The company earns most of its revenues from subsidiary OXIS Health Products, which makes medical instruments, diagnostic assays, and a cow enzyme to treat humans and animals. Its OXIS Therapeutics unit develops drugs: Its lead product, BXT-51072, is currently in clinical trials to treat inflammatory bowel disease, which is believed to be connected to oxidative stress. The company is also researching drugs for cardiovascular and neurodegenerative diseases, which may be related to oxidative stress as well. Swiss investment bank Pictet & Cie owns 25% of the firm.
COMPETITION |
 |
Beckman Coulter, Inc. (BEC)
Becton, Dickinson and Company (BDX)
Centaur Pharmaceuticals, Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 3.50
1-Yr. Sales Growth: (51.4)%
Employees: 52
Revenue per employee: $67,307.69
KEY PEOPLE |
 |
Joseph F. Bozman
CEO
Jon S. Pitcher
CFO
CONTACT INFO |
 |
6040 N. Cutter Circle, Ste. 317
Portland , OR 97217
US
Phone: 503-283-3911
Fax: 503-283-4058
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |